VERU Stock Analysis: Buy, Sell, or Hold?
VERU - Veru Inc.
$3.06
-0.10 (-3.16%)
▼
5d:
+4.08%
30d:
+30.21%
90d:
+34.8%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When VERU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VERU shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VERU shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VERU is currently trading at $3.06, which is considered fair relative to its 30-day fair value range of $2.50 to $3.34.
Technical Outlook: Technically, VERU is showing sideways momentum. Immediate support is located at $2.11, while resistance sits at $7.33. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.50 (+700.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VERU is showing sideways momentum. Immediate support is located at $2.11, while resistance sits at $7.33. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.50 (+700.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.50 -
$3.34
Company Quality Score
61/100
(BUY)
Volume Confirmation
MODERATE
Confidence Score
71.7%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 700.7% below Wall St target ($24.50)
Trading Range Analysis
30-Day Trading Range
$2.50 -
$3.34
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.68
(22.2%)
Support & Resistance Levels
Support Level
$2.11
Resistance Level
$7.33
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.11
Wall Street Target
$24.50
(+700.7%)
Revenue Growth (YoY)
18.3%
Share & Embed Analysis
Last updated: July 03, 2026 5:47 PM ET
Data refreshes hourly during market hours. Next update: 6:47 PM
Data refreshes hourly during market hours. Next update: 6:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VERU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
